Comparative Pharmacology
Head-to-head clinical analysis: KONVOMEP versus TIAGABINE HYDROCHLORIDE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: KONVOMEP versus TIAGABINE HYDROCHLORIDE.
KONVOMEP vs TIAGABINE HYDROCHLORIDE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Fosnetupitant is a neurokinin-1 (NK1) receptor antagonist that inhibits substance P binding; palonosetron is a serotonin-3 (5-HT3) receptor antagonist that blocks emetic signals in the chemoreceptor trigger zone and gastrointestinal tract.
Tiagabine inhibits GABA reuptake into presynaptic neurons and glial cells by binding to the GAT-1 GABA transporter, thereby increasing synaptic GABA concentrations and enhancing inhibitory neurotransmission.
IV: 8 mg (as netupitant 235 mg/palonosetron 0.25 mg combination) over 15 minutes on day 1 of chemotherapy.
Initial: 4 mg orally once daily; titrate by 4-8 mg/day at weekly intervals. Maintenance: 32-56 mg/day divided 2-4 times daily. Maximum dose: 56 mg/day.
None Documented
None Documented
Terminal elimination half-life: 8-12 hours in healthy adults. Extended to 18-24 hours in renal impairment (CrCl <30 mL/min).
Terminal half-life of 5–8 hours in healthy adults; prolonged to 12–16 hours in hepatic impairment. Reduces with enzyme-inducing co-medications.
Renal: approximately 70% as unchanged drug; fecal: approximately 20% as metabolites; biliary: negligible.
Primarily hepatic metabolism via CYP3A4, with <2% excreted unchanged in urine. 63% of dose excreted in feces, 25% in urine as metabolites.
Category C
Category A/B
Anticonvulsant
Anticonvulsant